Laura C. Michaelis, MD

home / authors / laura-c-michaelis-md

Articles

Laura C. Michaelis, MD, of the Medical College of Wisconsin

Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AML

Laura C. Michaelis, MD
June 21st 2021

Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.

Read More

Dr. Michaelis on the Role of Interferon in MPNs

Dr. Michaelis on the Role of Interferon in MPNs

Laura C. Michaelis, MD
May 4th 2020

Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.

Read More

Dr. Michaelis on Potential Combination Strategies With Ruxolitinib in Myelofibrosis

Dr. Michaelis on Potential Combination Strategies With Ruxolitinib in Myelofibrosis

Laura C. Michaelis, MD
April 22nd 2020

Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.

Read More

Dr. Michaelis on Unanswered Questions in Myelofibrosis Treatment

Dr. Michaelis on Unanswered Questions in Myelofibrosis Treatment

Laura C. Michaelis, MD
April 10th 2020

Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.

Read More

Dr. Michaelis on Treating Patients With Myelofibrosis and Anemia

Dr. Michaelis on Treating Patients With Myelofibrosis and Anemia

Laura C. Michaelis, MD
February 22nd 2020

Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.

Read More

Dr. Michaelis on Fedratinib in Myelofibrosis Treatment

Dr. Michaelis on Fedratinib in Myelofibrosis Treatment

Laura C. Michaelis, MD
September 13th 2019

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need